Related Experiment Video

Updated: Apr 30, 2026

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

10.4K

Vintafolide: a novel targeted agent for epithelial ovarian cancer

Whitney S Graybill1, Robert L Coleman

  • 1Medical University of South Carolina, Division of Gynecologic Oncology, 96 Jonathan Lucas Street, CSB 634, MSC 619, Charleston, SC, USA.

Future Oncology (London, England)
|April 24, 2014
PubMed

Insights

Vintafolide, a novel folate-drug conjugate, shows promise in treating ovarian cancer by targeting the folate receptor. Combination therapy with pegylated liposomal doxorubicin significantly improved progression-free survival in platinum-resistant cases.

Area of Science:

  • Oncology
  • Pharmacology
  • Radiopharmaceuticals

Background:

  • Vintafolide (EC145) is a novel folate-conjugated vinca alkaloid (desacetylvinblastine hydrazide; DAVBLH).
  • It exhibits high affinity binding to the folate receptor (FR), which is prevalent in epithelial ovarian cancers.
  • Preclinical studies indicated significant antiproliferative activity and good tolerability for vintafolide.

Purpose of the Study:

  • To evaluate the efficacy and safety of vintafolide in combination with pegylated liposomal doxorubicin (PLD) for platinum-resistant ovarian cancer.
  • To assess the role of (99m)Tc-etarfolatide in identifying patients likely to benefit from vintafolide treatment.

Main Methods:

  • Phase II study comparing vintafolide plus PLD versus PLD alone in platinum-resistant ovarian cancer.
  • Utilized (99m)Tc-etarfolatide to determine folate receptor (FR) status for patient selection.
  • Phase I studies established the safety profile and dose-limiting toxicity (constipation).

Main Results:

  • The combination of vintafolide and PLD demonstrated a statistically significant improvement in progression-free survival compared to PLD alone.
  • Phase I studies confirmed an acceptable safety profile for vintafolide.

Conclusions:

  • Vintafolide in combination with PLD offers a promising therapeutic strategy for patients with platinum-resistant ovarian cancer.
  • FR status, determined by (99m)Tc-etarfolatide, can guide treatment selection for vintafolide therapy.

More Related Videos

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting07:54

Surface-enhanced Resonance Raman Scattering Nanoprobe Ratiometry for Detecting Microscopic Ovarian Cancer via Folate Receptor Targeting

Published on: March 25, 2019

7.6K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

13.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
927
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121